Compass Therapeutics (NASDAQ:CMPX) Raised to “Hold” at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

A number of other research analysts also recently issued reports on the stock. Canaccord Genuity Group set a $13.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, February 4th. Citigroup initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. Leerink Partners upgraded shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. JMP Securities set a $10.00 target price on Compass Therapeutics in a report on Wednesday, December 3rd. Finally, Citizens Jmp started coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Compass Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $6.28 on Monday. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $6.88. The firm has a market cap of $1.12 billion, a P/E ratio of -13.96 and a beta of 1.46. The business’s 50 day moving average price is $5.67 and its 200-day moving average price is $4.51.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CMPX. Suvretta Capital Management LLC grew its stake in shares of Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after acquiring an additional 6,951,666 shares during the last quarter. Vivo Capital LLC boosted its stake in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after purchasing an additional 3,502,000 shares in the last quarter. Vanguard Group Inc. grew its position in Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after purchasing an additional 2,212,794 shares during the last quarter. State Street Corp increased its stake in Compass Therapeutics by 57.4% during the 4th quarter. State Street Corp now owns 4,890,525 shares of the company’s stock valued at $26,262,000 after purchasing an additional 1,784,012 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after purchasing an additional 449,868 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.